Piramal Pharma Limited — Board Meeting, 28-01-2025: Outcome of Board Meeting

The Board of Piramal Pharma Limited approved the consolidated and standalone financial results for the quarter and nine months ended December 31, 2024. Key highlights include revenue from operations of ₹1,248.32 Cr for the latest quarter, with a net profit after tax of ₹118.80 Cr. Additionally, the Board appointed Ms. Nathalie Leitch as an Additional Director (Non-Executive, Non-Independent), subject to shareholder approval. The company aims to enhance its strategic direction with this new appointment, reflecting its ongoing commitment to growth and operational excellence.